34 |
Klinisk Biokemi i Norden · 4 2015
Referanser:
1. Frassetto L, Kohlstadt I. Treatment and pre-
vention of kidney stones: an update. Am Fam
Physician 2011;84:1234-42.
2. Scales CD Jr, Smith AC, Hanley JM, Saigal
CS. Prevalence of kidney stones in the United
States. Eur Urol 2012;62:160-5.
3. Kohjimoto Y, Sasaki Y, Iguchi M, Iguchi M,
Matsumura N, Inagaki T, Hara I. Association
of metabolic syndrome traits and severity of
kidney stones: Results from a nationwide sur-
vey on urolithiasis in Japan. Am J Kidney Dis
2013;61:923-9.
4. Borghi L, Schianchi T, Meschi T, Guerra A,
Allegri F, Maggiore U, Novarini A. Compari-
son of two diets for the prevention of recurrent
stones in idiopathic hypercalciuria. N Engl J
Med 2002;346:77-84.
5. Türk C, Knoll T, Petrik A, Sarica K, Skolarikos
A, Straub M, Seitz C. Guidelines on urolithia-
sis. European Association of Urology 2014,
-
Urolithiasis_LR.pdf.
6. Karlsen SJ. Kirurgisk behandling av urolithia-
sis. Tidsskr Nor Lægeforen 2003;7:938-40.
7. Osther PJ, Grenabo L, Haraldsson G, Holm-
berg G, Lindell O, Mogensen P et al. Meta-
bolic evaluation and medical management of
upper urinary tract stone disease. Guidelines
from the Scandinavian Cooperative Group
for Urinary Stones. Scand J Urol Nephrol
1999;33:372-81.
8. Zeng G, Zhao Z, Wu W, Ou L, Liang Y, Yuan J
.
Interconversion of stone composition profiles
from two recurrent stone episodes in stone
formers. Clin Chem Lab Med 2014;52:1019-24.
9. Hesse A, Kruse R, Geilenkeuser WJ, Schmidt
M. Quality control in urinary stone analysis:
results of 44 ring trials (1980–2001). Clin
Chem Lab Med 2005;43:298-303.
Blærestein (den øverste) og nyresteiner (de øvrige).
Foto: artikkelforfatterne.
